| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Animals | 116 | 2024 | 10583 | 0.800 |
Why?
|
| Glioma | 8 | 2020 | 121 | 0.760 |
Why?
|
| Rats | 67 | 2021 | 1587 | 0.760 |
Why?
|
| Brain Neoplasms | 7 | 2022 | 311 | 0.720 |
Why?
|
| Pancreatic Neoplasms | 13 | 2016 | 548 | 0.660 |
Why?
|
| Biomarkers, Tumor | 10 | 2017 | 410 | 0.640 |
Why?
|
| Adenocarcinoma | 10 | 2017 | 300 | 0.590 |
Why?
|
| Melanophores | 9 | 2001 | 10 | 0.580 |
Why?
|
| Cloning, Molecular | 14 | 2002 | 208 | 0.510 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2021 | 834 | 0.510 |
Why?
|
| Glioblastoma | 3 | 2022 | 109 | 0.480 |
Why?
|
| Receptors, G-Protein-Coupled | 4 | 2021 | 78 | 0.480 |
Why?
|
| Male | 75 | 2025 | 13772 | 0.440 |
Why?
|
| Brain | 12 | 2021 | 753 | 0.430 |
Why?
|
| Rats, Sprague-Dawley | 34 | 2018 | 554 | 0.430 |
Why?
|
| Receptors, Cell Surface | 6 | 2006 | 114 | 0.430 |
Why?
|
| Peptides | 7 | 1998 | 293 | 0.410 |
Why?
|
| DNA | 13 | 2001 | 375 | 0.410 |
Why?
|
| Mice | 33 | 2023 | 4735 | 0.400 |
Why?
|
| Amino Acid Sequence | 21 | 2008 | 695 | 0.400 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2024 | 340 | 0.390 |
Why?
|
| Disease Models, Animal | 23 | 2021 | 1494 | 0.390 |
Why?
|
| Carrier Proteins | 5 | 2015 | 252 | 0.380 |
Why?
|
| Ribonucleoproteins | 6 | 1992 | 154 | 0.380 |
Why?
|
| Molecular Sequence Data | 22 | 2008 | 1056 | 0.370 |
Why?
|
| Humans | 64 | 2025 | 28585 | 0.360 |
Why?
|
| Hemodynamics | 19 | 1999 | 221 | 0.340 |
Why?
|
| Blast Injuries | 5 | 2016 | 35 | 0.320 |
Why?
|
| Shock, Septic | 11 | 1997 | 38 | 0.320 |
Why?
|
| Female | 43 | 2025 | 15472 | 0.320 |
Why?
|
| Lung Neoplasms | 4 | 2017 | 357 | 0.320 |
Why?
|
| Receptors, Odorant | 3 | 1997 | 7 | 0.310 |
Why?
|
| Cystitis, Interstitial | 2 | 2020 | 17 | 0.310 |
Why?
|
| Antibodies, Monoclonal | 5 | 2021 | 333 | 0.300 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2017 | 105 | 0.300 |
Why?
|
| Base Sequence | 17 | 2016 | 588 | 0.300 |
Why?
|
| Blood Proteins | 4 | 2020 | 68 | 0.300 |
Why?
|
| Urinary Bladder | 2 | 2020 | 119 | 0.290 |
Why?
|
| Magnetic Resonance Spectroscopy | 4 | 2018 | 180 | 0.290 |
Why?
|
| Coronary Artery Disease | 2 | 2021 | 218 | 0.290 |
Why?
|
| Xenopus laevis | 8 | 2001 | 50 | 0.280 |
Why?
|
| GTP-Binding Proteins | 4 | 1998 | 46 | 0.280 |
Why?
|
| Peptide Library | 2 | 1998 | 26 | 0.280 |
Why?
|
| Endotoxins | 16 | 1996 | 28 | 0.280 |
Why?
|
| Cell Line, Tumor | 14 | 2021 | 1341 | 0.270 |
Why?
|
| Breast Neoplasms | 7 | 2015 | 472 | 0.260 |
Why?
|
| Benzenesulfonates | 3 | 2021 | 18 | 0.250 |
Why?
|
| Imines | 3 | 2021 | 21 | 0.250 |
Why?
|
| Blood-Brain Barrier | 3 | 2021 | 83 | 0.240 |
Why?
|
| Antimicrobial Cationic Peptides | 4 | 2015 | 34 | 0.240 |
Why?
|
| Neurons | 3 | 1993 | 291 | 0.240 |
Why?
|
| Cardiovascular Diseases | 3 | 2024 | 373 | 0.230 |
Why?
|
| MicroRNAs | 4 | 2011 | 301 | 0.230 |
Why?
|
| Glutathione Peroxidase | 1 | 2025 | 26 | 0.230 |
Why?
|
| Inflammation | 6 | 2023 | 642 | 0.230 |
Why?
|
| Aged | 17 | 2024 | 5525 | 0.230 |
Why?
|
| Antioxidants | 4 | 2015 | 224 | 0.220 |
Why?
|
| Autoantigens | 3 | 1992 | 212 | 0.220 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 6 | 2020 | 72 | 0.220 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2019 | 275 | 0.220 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2016 | 146 | 0.220 |
Why?
|
| Middle Aged | 18 | 2024 | 7310 | 0.220 |
Why?
|
| Cell Movement | 5 | 2022 | 373 | 0.220 |
Why?
|
| Lipid Metabolism | 1 | 2025 | 135 | 0.220 |
Why?
|
| Iron | 1 | 2025 | 117 | 0.210 |
Why?
|
| Pancreas | 5 | 2015 | 63 | 0.210 |
Why?
|
| Proteomics | 2 | 2017 | 192 | 0.210 |
Why?
|
| Exoribonucleases | 2 | 2022 | 20 | 0.210 |
Why?
|
| Lipids | 1 | 2025 | 214 | 0.210 |
Why?
|
| Endotoxemia | 3 | 2018 | 8 | 0.210 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2006 | 233 | 0.210 |
Why?
|
| Zebrafish | 1 | 2024 | 96 | 0.200 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2017 | 163 | 0.200 |
Why?
|
| Colon | 2 | 2018 | 121 | 0.200 |
Why?
|
| Abdominal Wall | 1 | 2023 | 9 | 0.200 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2025 | 103 | 0.200 |
Why?
|
| RNA, Messenger | 9 | 2022 | 667 | 0.200 |
Why?
|
| Gene Expression | 8 | 2011 | 417 | 0.190 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2020 | 115 | 0.190 |
Why?
|
| Immunohistochemistry | 11 | 2020 | 465 | 0.190 |
Why?
|
| Corpus Striatum | 2 | 1993 | 23 | 0.190 |
Why?
|
| Molecular Probes | 2 | 2020 | 13 | 0.190 |
Why?
|
| Liver | 8 | 2009 | 456 | 0.190 |
Why?
|
| Genetic Variation | 2 | 2021 | 245 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 10 | 2013 | 270 | 0.190 |
Why?
|
| Inflammation Mediators | 3 | 2015 | 166 | 0.190 |
Why?
|
| Moths | 3 | 1997 | 13 | 0.180 |
Why?
|
| Apolipoprotein C-III | 1 | 2021 | 12 | 0.180 |
Why?
|
| Free Radicals | 6 | 2015 | 39 | 0.180 |
Why?
|
| Adult | 16 | 2024 | 7922 | 0.180 |
Why?
|
| alpha-MSH | 3 | 1998 | 7 | 0.180 |
Why?
|
| Cells, Cultured | 12 | 2015 | 1009 | 0.180 |
Why?
|
| RNA | 9 | 2008 | 111 | 0.180 |
Why?
|
| Blood Glucose | 10 | 2024 | 310 | 0.180 |
Why?
|
| Pancreatitis, Chronic | 2 | 2015 | 7 | 0.180 |
Why?
|
| Case-Control Studies | 7 | 2020 | 732 | 0.170 |
Why?
|
| Brain Stem Neoplasms | 1 | 2020 | 12 | 0.170 |
Why?
|
| Claudin-2 | 1 | 2020 | 4 | 0.170 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2000 | 4 | 0.170 |
Why?
|
| Cell Proliferation | 5 | 2022 | 817 | 0.170 |
Why?
|
| Gene Expression Profiling | 3 | 2008 | 453 | 0.170 |
Why?
|
| Sirolimus | 1 | 2021 | 76 | 0.170 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2021 | 50 | 0.160 |
Why?
|
| Signal Transduction | 3 | 2014 | 1455 | 0.160 |
Why?
|
| Parathyroid Hormone | 1 | 2020 | 24 | 0.160 |
Why?
|
| Macrophages | 3 | 2020 | 302 | 0.160 |
Why?
|
| Diabetic Angiopathies | 1 | 2020 | 48 | 0.160 |
Why?
|
| Cytokines | 3 | 2020 | 448 | 0.160 |
Why?
|
| TRPC Cation Channels | 1 | 2020 | 34 | 0.160 |
Why?
|
| Neovascularization, Pathologic | 3 | 2017 | 148 | 0.160 |
Why?
|
| Contrast Media | 2 | 2018 | 96 | 0.160 |
Why?
|
| Multiple Sclerosis | 1 | 2021 | 89 | 0.160 |
Why?
|
| Colorectal Neoplasms | 2 | 2020 | 141 | 0.160 |
Why?
|
| Transfection | 7 | 2000 | 319 | 0.160 |
Why?
|
| Diagnosis, Differential | 6 | 2019 | 378 | 0.160 |
Why?
|
| Protein Sorting Signals | 3 | 1999 | 18 | 0.160 |
Why?
|
| War-Related Injuries | 1 | 2019 | 2 | 0.150 |
Why?
|
| Post-Concussion Syndrome | 1 | 2019 | 4 | 0.150 |
Why?
|
| Migraine Disorders | 1 | 2019 | 22 | 0.150 |
Why?
|
| Early Detection of Cancer | 4 | 2015 | 132 | 0.150 |
Why?
|
| Cocaine | 3 | 2005 | 22 | 0.150 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2019 | 41 | 0.150 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 3 | 2015 | 13 | 0.150 |
Why?
|
| Aged, 80 and over | 8 | 2017 | 2045 | 0.140 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 285 | 0.140 |
Why?
|
| Veterans | 1 | 2019 | 69 | 0.140 |
Why?
|
| Sepsis-Associated Encephalopathy | 1 | 2018 | 3 | 0.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 6 | 2008 | 194 | 0.140 |
Why?
|
| Proteoglycans | 1 | 2018 | 38 | 0.140 |
Why?
|
| Hydrocarbons | 2 | 2010 | 41 | 0.140 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2018 | 32 | 0.140 |
Why?
|
| Receptors, Adrenergic | 1 | 1997 | 10 | 0.140 |
Why?
|
| Prunus | 2 | 2008 | 3 | 0.140 |
Why?
|
| Transcription Factors | 5 | 2011 | 523 | 0.140 |
Why?
|
| Phenotype | 4 | 2020 | 682 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2016 | 465 | 0.130 |
Why?
|
| Conserved Sequence | 2 | 2016 | 54 | 0.130 |
Why?
|
| Neoplasm Staging | 6 | 2017 | 478 | 0.130 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 681 | 0.130 |
Why?
|
| Cycloheptanes | 1 | 2016 | 4 | 0.130 |
Why?
|
| Hypoxia, Brain | 1 | 2016 | 5 | 0.130 |
Why?
|
| RNA, Untranslated | 1 | 2016 | 9 | 0.130 |
Why?
|
| Lipopolysaccharides | 7 | 2020 | 157 | 0.130 |
Why?
|
| Narcotic Antagonists | 1 | 2016 | 32 | 0.130 |
Why?
|
| Piperidines | 1 | 2016 | 48 | 0.120 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 1993 | 38 | 0.120 |
Why?
|
| Brain Concussion | 1 | 2016 | 52 | 0.120 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2017 | 108 | 0.120 |
Why?
|
| Mammary Neoplasms, Experimental | 3 | 2003 | 48 | 0.120 |
Why?
|
| Myocardium | 8 | 2007 | 194 | 0.120 |
Why?
|
| Mice, Nude | 6 | 2017 | 332 | 0.120 |
Why?
|
| Repressor Proteins | 3 | 2011 | 119 | 0.120 |
Why?
|
| Osteoporosis | 2 | 2006 | 63 | 0.120 |
Why?
|
| Immunity, Innate | 3 | 2020 | 231 | 0.120 |
Why?
|
| Pyramidal Cells | 1 | 2015 | 14 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 7 | 2017 | 314 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2013 | 611 | 0.110 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 1994 | 5 | 0.110 |
Why?
|
| Staphylococcal Infections | 2 | 2012 | 87 | 0.110 |
Why?
|
| Biomarkers | 5 | 2021 | 770 | 0.110 |
Why?
|
| Protein Kinase C-delta | 1 | 2014 | 6 | 0.110 |
Why?
|
| Smell | 2 | 1992 | 13 | 0.110 |
Why?
|
| Eye Injuries | 1 | 2014 | 11 | 0.110 |
Why?
|
| Receptors, sigma | 2 | 2005 | 5 | 0.110 |
Why?
|
| Casein Kinase II | 1 | 2014 | 17 | 0.110 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2014 | 2 | 0.110 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2014 | 5 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1994 | 97 | 0.110 |
Why?
|
| Pentoxifylline | 1 | 1994 | 2 | 0.110 |
Why?
|
| 3' Untranslated Regions | 2 | 2004 | 34 | 0.110 |
Why?
|
| Telomere | 1 | 2014 | 36 | 0.110 |
Why?
|
| Gene Library | 6 | 1997 | 45 | 0.110 |
Why?
|
| Fibroblast Growth Factor 7 | 3 | 2009 | 5 | 0.110 |
Why?
|
| Flax | 1 | 2013 | 2 | 0.110 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2011 | 28 | 0.110 |
Why?
|
| Isoflavones | 1 | 2013 | 8 | 0.110 |
Why?
|
| Cornea | 1 | 2014 | 72 | 0.110 |
Why?
|
| Leukocytes | 1 | 2014 | 72 | 0.100 |
Why?
|
| Hypercholesterolemia | 1 | 2013 | 18 | 0.100 |
Why?
|
| Receptors, Endothelin | 1 | 1993 | 2 | 0.100 |
Why?
|
| Phytotherapy | 1 | 2013 | 22 | 0.100 |
Why?
|
| Up-Regulation | 6 | 2015 | 247 | 0.100 |
Why?
|
| Endothelins | 1 | 1993 | 7 | 0.100 |
Why?
|
| Time Factors | 10 | 2013 | 1600 | 0.100 |
Why?
|
| Receptors, Dopamine | 1 | 1993 | 3 | 0.100 |
Why?
|
| Basal Ganglia | 1 | 1993 | 10 | 0.100 |
Why?
|
| Wound Healing | 1 | 2014 | 126 | 0.100 |
Why?
|
| Genes | 2 | 1990 | 36 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 164 | 0.100 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2013 | 8 | 0.100 |
Why?
|
| Genetic Carrier Screening | 1 | 2013 | 10 | 0.100 |
Why?
|
| Frameshift Mutation | 1 | 2013 | 14 | 0.100 |
Why?
|
| Membrane Glycoproteins | 2 | 2005 | 147 | 0.100 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2013 | 48 | 0.100 |
Why?
|
| Brain Injuries | 1 | 2013 | 50 | 0.100 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 5 | 1992 | 41 | 0.100 |
Why?
|
| Wnt Proteins | 1 | 2013 | 34 | 0.100 |
Why?
|
| Cardiovascular System | 6 | 1997 | 40 | 0.100 |
Why?
|
| Biomimetic Materials | 1 | 2013 | 20 | 0.100 |
Why?
|
| Alzheimer Disease | 1 | 2015 | 223 | 0.100 |
Why?
|
| Phosphoproteins | 1 | 1993 | 120 | 0.100 |
Why?
|
| Neoplasms, Experimental | 1 | 2013 | 58 | 0.100 |
Why?
|
| Silicon Dioxide | 1 | 2013 | 43 | 0.100 |
Why?
|
| Nervous System Physiological Phenomena | 1 | 1992 | 3 | 0.100 |
Why?
|
| Polyethylene Terephthalates | 1 | 2012 | 7 | 0.100 |
Why?
|
| Cell Line | 7 | 2008 | 698 | 0.100 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2012 | 28 | 0.090 |
Why?
|
| Prosthesis-Related Infections | 1 | 2012 | 14 | 0.090 |
Why?
|
| Bioprosthesis | 1 | 2012 | 21 | 0.090 |
Why?
|
| Predictive Value of Tests | 4 | 2017 | 480 | 0.090 |
Why?
|
| Bombesin | 3 | 1998 | 10 | 0.090 |
Why?
|
| Escherichia coli | 7 | 1997 | 338 | 0.090 |
Why?
|
| Tissue Scaffolds | 1 | 2013 | 88 | 0.090 |
Why?
|
| Extracellular Matrix | 1 | 2013 | 117 | 0.090 |
Why?
|
| Tumor Burden | 3 | 2019 | 110 | 0.090 |
Why?
|
| Kidney | 6 | 2005 | 286 | 0.090 |
Why?
|
| Membrane Proteins | 3 | 2001 | 485 | 0.090 |
Why?
|
| DNA-Binding Proteins | 3 | 2005 | 490 | 0.090 |
Why?
|
| Models, Animal | 1 | 2012 | 130 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 5 | 2021 | 1602 | 0.090 |
Why?
|
| Oligonucleotides, Antisense | 3 | 2003 | 22 | 0.090 |
Why?
|
| Cognition Disorders | 1 | 2013 | 186 | 0.090 |
Why?
|
| Insecta | 1 | 1991 | 24 | 0.090 |
Why?
|
| Swine | 1 | 2012 | 238 | 0.090 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1991 | 39 | 0.090 |
Why?
|
| Nitrogen Oxides | 2 | 2021 | 41 | 0.090 |
Why?
|
| Tissue Engineering | 1 | 2013 | 152 | 0.090 |
Why?
|
| Phenols | 2 | 2008 | 22 | 0.090 |
Why?
|
| Flavonoids | 2 | 2008 | 32 | 0.090 |
Why?
|
| Retinoblastoma Protein | 1 | 2011 | 10 | 0.090 |
Why?
|
| Metabolomics | 1 | 2012 | 87 | 0.090 |
Why?
|
| Sense Organs | 1 | 1991 | 4 | 0.090 |
Why?
|
| Sepsis | 2 | 2009 | 86 | 0.090 |
Why?
|
| Recombinant Proteins | 5 | 2018 | 415 | 0.090 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2011 | 58 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 56 | 0.090 |
Why?
|
| Molecular Imaging | 1 | 2011 | 35 | 0.090 |
Why?
|
| Transcription, Genetic | 5 | 1994 | 404 | 0.080 |
Why?
|
| Insect Proteins | 2 | 1997 | 12 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2011 | 328 | 0.080 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2011 | 115 | 0.080 |
Why?
|
| Neoplasm Transplantation | 3 | 2020 | 90 | 0.080 |
Why?
|
| Hepatocytes | 2 | 2009 | 80 | 0.080 |
Why?
|
| Proteins | 3 | 2003 | 253 | 0.080 |
Why?
|
| Apoptosis | 3 | 2017 | 777 | 0.080 |
Why?
|
| Escherichia coli Infections | 3 | 1994 | 45 | 0.080 |
Why?
|
| Pigments, Biological | 3 | 2000 | 8 | 0.080 |
Why?
|
| Autoantibodies | 2 | 1991 | 479 | 0.080 |
Why?
|
| DNA, Complementary | 5 | 2005 | 78 | 0.080 |
Why?
|
| Permeability | 2 | 2020 | 61 | 0.080 |
Why?
|
| Neutrophils | 3 | 1996 | 183 | 0.080 |
Why?
|
| Leuprolide | 2 | 1999 | 5 | 0.080 |
Why?
|
| Insect Hormones | 1 | 1988 | 8 | 0.070 |
Why?
|
| Hemin | 1 | 2008 | 14 | 0.070 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 1999 | 29 | 0.070 |
Why?
|
| Dietary Supplements | 2 | 2013 | 265 | 0.070 |
Why?
|
| Callithrix | 1 | 2008 | 2 | 0.070 |
Why?
|
| Ovariectomy | 2 | 1999 | 53 | 0.070 |
Why?
|
| Antibodies | 4 | 2020 | 124 | 0.070 |
Why?
|
| Pigment Epithelium of Eye | 1 | 2008 | 15 | 0.070 |
Why?
|
| Heart Rate | 10 | 1999 | 380 | 0.070 |
Why?
|
| Rats, Inbred Strains | 12 | 1991 | 63 | 0.070 |
Why?
|
| Random Allocation | 5 | 2018 | 151 | 0.070 |
Why?
|
| Antigens, Ly | 1 | 2008 | 9 | 0.070 |
Why?
|
| NFATC Transcription Factors | 1 | 2008 | 14 | 0.070 |
Why?
|
| Refraction, Ocular | 1 | 2008 | 25 | 0.070 |
Why?
|
| Choroid | 1 | 2008 | 20 | 0.070 |
Why?
|
| Autophagy | 1 | 2009 | 74 | 0.070 |
Why?
|
| Gene Expression Regulation | 2 | 2008 | 633 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 285 | 0.070 |
Why?
|
| HeLa Cells | 4 | 1993 | 208 | 0.070 |
Why?
|
| Nitric Oxide | 3 | 2008 | 152 | 0.070 |
Why?
|
| Pneumocystis | 1 | 1988 | 1 | 0.070 |
Why?
|
| Ligands | 2 | 2000 | 178 | 0.070 |
Why?
|
| India | 2 | 2021 | 143 | 0.070 |
Why?
|
| Listeriosis | 1 | 2008 | 41 | 0.070 |
Why?
|
| Osteoclasts | 1 | 2008 | 32 | 0.070 |
Why?
|
| Enterococcus faecalis | 1 | 2008 | 71 | 0.070 |
Why?
|
| Cell Adhesion | 3 | 2017 | 139 | 0.070 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2007 | 8 | 0.070 |
Why?
|
| Structure-Activity Relationship | 3 | 2007 | 209 | 0.070 |
Why?
|
| Lung | 5 | 2001 | 380 | 0.070 |
Why?
|
| Gene Targeting | 1 | 2007 | 21 | 0.070 |
Why?
|
| Kidney Glomerulus | 2 | 2000 | 15 | 0.070 |
Why?
|
| Chronic Disease | 4 | 2019 | 273 | 0.070 |
Why?
|
| Cerebrovascular Circulation | 2 | 2021 | 224 | 0.070 |
Why?
|
| Cardiac Output | 8 | 1995 | 36 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2024 | 550 | 0.070 |
Why?
|
| Intestine, Small | 4 | 1996 | 66 | 0.070 |
Why?
|
| Fibroblasts | 4 | 2008 | 160 | 0.070 |
Why?
|
| Models, Genetic | 1 | 2007 | 125 | 0.070 |
Why?
|
| Sequence Analysis, RNA | 1 | 2007 | 58 | 0.070 |
Why?
|
| RNA, Neoplasm | 2 | 2005 | 24 | 0.070 |
Why?
|
| Triglycerides | 2 | 2021 | 123 | 0.070 |
Why?
|
| Isoenzymes | 2 | 2008 | 86 | 0.070 |
Why?
|
| Monocytes | 1 | 2008 | 135 | 0.070 |
Why?
|
| Retrospective Studies | 3 | 2020 | 2612 | 0.070 |
Why?
|
| Fibroblast Growth Factors | 2 | 2004 | 24 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2024 | 671 | 0.060 |
Why?
|
| Sequence Homology, Amino Acid | 5 | 2002 | 133 | 0.060 |
Why?
|
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2006 | 6 | 0.060 |
Why?
|
| Reproducibility of Results | 4 | 2011 | 782 | 0.060 |
Why?
|
| Rats, Inbred F344 | 3 | 2011 | 174 | 0.060 |
Why?
|
| Blotting, Southern | 3 | 1992 | 27 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2015 | 247 | 0.060 |
Why?
|
| Carbon-Sulfur Lyases | 1 | 2006 | 16 | 0.060 |
Why?
|
| Reference Values | 4 | 2018 | 199 | 0.060 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2018 | 57 | 0.060 |
Why?
|
| Ethanol | 2 | 1999 | 124 | 0.060 |
Why?
|
| Cell Division | 3 | 2011 | 154 | 0.060 |
Why?
|
| Nitric Oxide Synthase | 2 | 2008 | 34 | 0.060 |
Why?
|
| Uridine | 1 | 2005 | 8 | 0.060 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 1991 | 992 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2011 | 595 | 0.060 |
Why?
|
| Down-Regulation | 3 | 2008 | 200 | 0.060 |
Why?
|
| Coronary Disease | 1 | 2005 | 120 | 0.060 |
Why?
|
| Protein Biosynthesis | 3 | 2003 | 111 | 0.060 |
Why?
|
| Reward | 1 | 2005 | 46 | 0.060 |
Why?
|
| Motor Activity | 3 | 2016 | 148 | 0.060 |
Why?
|
| Coronary Vessels | 1 | 2005 | 153 | 0.050 |
Why?
|
| Organ Specificity | 3 | 1996 | 82 | 0.050 |
Why?
|
| Blotting, Western | 3 | 2011 | 515 | 0.050 |
Why?
|
| Alleles | 2 | 2021 | 354 | 0.050 |
Why?
|
| Bone Demineralization, Pathologic | 1 | 2004 | 1 | 0.050 |
Why?
|
| Hindlimb Suspension | 1 | 2004 | 8 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 2 | 1997 | 154 | 0.050 |
Why?
|
| Vitamin E | 1 | 2004 | 11 | 0.050 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2006 | 301 | 0.050 |
Why?
|
| Kinetics | 5 | 2003 | 551 | 0.050 |
Why?
|
| Free Radical Scavengers | 1 | 2004 | 23 | 0.050 |
Why?
|
| DNA, Recombinant | 2 | 1998 | 10 | 0.050 |
Why?
|
| Mutation, Missense | 1 | 2024 | 70 | 0.050 |
Why?
|
| MCF-7 Cells | 2 | 2015 | 34 | 0.050 |
Why?
|
| Heart | 1 | 2005 | 224 | 0.050 |
Why?
|
| Glucose | 1 | 2005 | 208 | 0.050 |
Why?
|
| Methods | 2 | 1998 | 27 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 3 | 2015 | 278 | 0.050 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2003 | 4 | 0.050 |
Why?
|
| Digestive System Neoplasms | 1 | 2003 | 5 | 0.050 |
Why?
|
| Oxidative Stress | 2 | 2025 | 671 | 0.050 |
Why?
|
| RNA Interference | 2 | 2016 | 137 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2003 | 39 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 164 | 0.050 |
Why?
|
| Technology, Pharmaceutical | 1 | 2003 | 9 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 2 | 2021 | 376 | 0.050 |
Why?
|
| Precancerous Conditions | 2 | 2003 | 39 | 0.050 |
Why?
|
| Oklahoma | 2 | 2020 | 1038 | 0.050 |
Why?
|
| Bacteremia | 2 | 1994 | 81 | 0.050 |
Why?
|
| Mutation | 2 | 2021 | 864 | 0.050 |
Why?
|
| Tissue Adhesions | 1 | 2023 | 4 | 0.050 |
Why?
|
| DNA, Neoplasm | 1 | 2003 | 34 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 1 | 2003 | 49 | 0.050 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 1993 | 24 | 0.050 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2002 | 4 | 0.050 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 6 | 0.050 |
Why?
|
| Lymphokines | 1 | 2002 | 8 | 0.050 |
Why?
|
| Immunotoxins | 1 | 2002 | 3 | 0.050 |
Why?
|
| Glutathione Transferase | 1 | 2002 | 33 | 0.050 |
Why?
|
| Dimethyl Sulfoxide | 2 | 1994 | 11 | 0.050 |
Why?
|
| Lactates | 5 | 1994 | 20 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 3 | 2009 | 66 | 0.050 |
Why?
|
| Exosomes | 1 | 2024 | 96 | 0.050 |
Why?
|
| Substance-Related Disorders | 1 | 2005 | 187 | 0.050 |
Why?
|
| Brain Chemistry | 3 | 2005 | 22 | 0.050 |
Why?
|
| Neoplastic Processes | 1 | 2022 | 4 | 0.050 |
Why?
|
| Hydrogels | 1 | 2023 | 59 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2020 | 862 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2016 | 509 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2002 | 67 | 0.050 |
Why?
|
| Sensitivity and Specificity | 3 | 2011 | 524 | 0.050 |
Why?
|
| Genital Neoplasms, Female | 1 | 2002 | 67 | 0.050 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 4 | 2005 | 15 | 0.050 |
Why?
|
| Splanchnic Circulation | 2 | 1995 | 7 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2025 | 899 | 0.050 |
Why?
|
| Receptors, Leukotriene | 1 | 2001 | 2 | 0.050 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2021 | 8 | 0.050 |
Why?
|
| Cricetinae | 3 | 2013 | 131 | 0.040 |
Why?
|
| Oligonucleotide Probes | 2 | 1992 | 18 | 0.040 |
Why?
|
| Heterozygote | 1 | 2021 | 69 | 0.040 |
Why?
|
| Europe | 1 | 2021 | 99 | 0.040 |
Why?
|
| Evolution, Molecular | 1 | 2002 | 85 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 115 | 0.040 |
Why?
|
| Electron Transport Complex IV | 2 | 1991 | 40 | 0.040 |
Why?
|
| Risk | 1 | 2021 | 137 | 0.040 |
Why?
|
| Arterioles | 2 | 2007 | 61 | 0.040 |
Why?
|
| Immune Sera | 2 | 1993 | 22 | 0.040 |
Why?
|
| Macromolecular Substances | 2 | 1992 | 53 | 0.040 |
Why?
|
| Embryonic and Fetal Development | 1 | 2001 | 9 | 0.040 |
Why?
|
| Protons | 2 | 2011 | 54 | 0.040 |
Why?
|
| Betamethasone | 1 | 2001 | 14 | 0.040 |
Why?
|
| Vascular Resistance | 7 | 1995 | 50 | 0.040 |
Why?
|
| Thrombosis | 2 | 2000 | 150 | 0.040 |
Why?
|
| Gadolinium DTPA | 1 | 2020 | 14 | 0.040 |
Why?
|
| snRNP Core Proteins | 2 | 1992 | 33 | 0.040 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 1991 | 48 | 0.040 |
Why?
|
| Salmon | 1 | 2000 | 2 | 0.040 |
Why?
|
| Patched Receptors | 1 | 2000 | 4 | 0.040 |
Why?
|
| Lung Injury | 2 | 1998 | 32 | 0.040 |
Why?
|
| Smoothened Receptor | 1 | 2000 | 9 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2003 | 236 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2020 | 35 | 0.040 |
Why?
|
| Mass Spectrometry | 2 | 2011 | 191 | 0.040 |
Why?
|
| Renal Circulation | 1 | 2000 | 7 | 0.040 |
Why?
|
| Morphine | 2 | 1999 | 29 | 0.040 |
Why?
|
| Blotting, Northern | 2 | 1991 | 46 | 0.040 |
Why?
|
| Restriction Mapping | 2 | 1991 | 23 | 0.040 |
Why?
|
| Systems Biology | 1 | 2020 | 22 | 0.040 |
Why?
|
| Nucleic Acid Hybridization | 2 | 1992 | 77 | 0.040 |
Why?
|
| Parathyroid Glands | 1 | 2020 | 7 | 0.040 |
Why?
|
| Bone Density | 3 | 2006 | 101 | 0.040 |
Why?
|
| Genotype | 1 | 2021 | 461 | 0.040 |
Why?
|
| Hypercalcemia | 1 | 2020 | 13 | 0.040 |
Why?
|
| DNA Primers | 3 | 2013 | 147 | 0.040 |
Why?
|
| In Vitro Techniques | 2 | 2000 | 242 | 0.040 |
Why?
|
| Adaptive Immunity | 1 | 2020 | 38 | 0.040 |
Why?
|
| Thyrotropin-Releasing Hormone | 2 | 1990 | 12 | 0.040 |
Why?
|
| Coronary Artery Bypass | 1 | 2020 | 68 | 0.040 |
Why?
|
| RGS Proteins | 1 | 1999 | 5 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2001 | 128 | 0.040 |
Why?
|
| Molecular Weight | 2 | 2005 | 122 | 0.040 |
Why?
|
| Receptors, Opioid, mu | 1 | 1999 | 22 | 0.040 |
Why?
|
| Chickens | 1 | 2019 | 62 | 0.040 |
Why?
|
| Cyclins | 1 | 1999 | 8 | 0.040 |
Why?
|
| Central Nervous System Depressants | 1 | 1999 | 13 | 0.040 |
Why?
|
| Calcium Signaling | 1 | 2020 | 72 | 0.040 |
Why?
|
| Endothelium, Vascular | 2 | 2000 | 328 | 0.040 |
Why?
|
| Receptors, Notch | 1 | 2019 | 44 | 0.040 |
Why?
|
| Barrett Esophagus | 1 | 1999 | 16 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 1999 | 34 | 0.040 |
Why?
|
| Shock, Traumatic | 1 | 1999 | 3 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 288 | 0.040 |
Why?
|
| Enflurane | 2 | 1989 | 2 | 0.040 |
Why?
|
| Lactic Acid | 4 | 2012 | 94 | 0.040 |
Why?
|
| Afghan Campaign 2001- | 1 | 2019 | 11 | 0.040 |
Why?
|
| Iraq War, 2003-2011 | 1 | 2019 | 11 | 0.040 |
Why?
|
| Esophageal Neoplasms | 1 | 1999 | 32 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2020 | 172 | 0.040 |
Why?
|
| Microvessels | 1 | 2019 | 86 | 0.040 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1999 | 41 | 0.040 |
Why?
|
| Ketamine | 2 | 1989 | 10 | 0.040 |
Why?
|
| Portal System | 2 | 1995 | 3 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2014 | 581 | 0.040 |
Why?
|
| Spin Trapping | 2 | 2015 | 13 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 1998 | 24 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1999 | 104 | 0.040 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 1998 | 21 | 0.040 |
Why?
|
| Spinal Cord | 1 | 2021 | 211 | 0.040 |
Why?
|
| Vagus Nerve | 1 | 1999 | 106 | 0.040 |
Why?
|
| Mammary Glands, Animal | 1 | 1998 | 33 | 0.040 |
Why?
|
| Reflex | 1 | 1999 | 74 | 0.040 |
Why?
|
| Melatonin | 2 | 1999 | 23 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 186 | 0.040 |
Why?
|
| Isoflurane | 2 | 1989 | 5 | 0.040 |
Why?
|
| Cyclic N-Oxides | 2 | 2015 | 26 | 0.040 |
Why?
|
| Neoplasms | 1 | 2007 | 857 | 0.040 |
Why?
|
| Administration, Intravesical | 1 | 2018 | 16 | 0.040 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2019 | 69 | 0.040 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1998 | 52 | 0.040 |
Why?
|
| Indicators and Reagents | 1 | 1998 | 26 | 0.040 |
Why?
|
| Estrogen Antagonists | 1 | 1998 | 16 | 0.040 |
Why?
|
| Ischemia | 2 | 1995 | 83 | 0.030 |
Why?
|
| Tamoxifen | 1 | 1998 | 33 | 0.030 |
Why?
|
| Databases, Protein | 1 | 2017 | 22 | 0.030 |
Why?
|
| Heart Injuries | 1 | 1997 | 8 | 0.030 |
Why?
|
| Adenylyl Cyclases | 1 | 1997 | 14 | 0.030 |
Why?
|
| Protein Kinase C | 2 | 1994 | 74 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 478 | 0.030 |
Why?
|
| Olfactory Receptor Neurons | 1 | 1997 | 4 | 0.030 |
Why?
|
| CD36 Antigens | 1 | 1997 | 8 | 0.030 |
Why?
|
| Iodine Radioisotopes | 2 | 1996 | 36 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2008 | 169 | 0.030 |
Why?
|
| Polyphenols | 2 | 2008 | 17 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1998 | 131 | 0.030 |
Why?
|
| Young Adult | 2 | 2015 | 2804 | 0.030 |
Why?
|
| Hypoglycemia | 2 | 1995 | 34 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 1997 | 267 | 0.030 |
Why?
|
| Plasmids | 2 | 1999 | 126 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2017 | 90 | 0.030 |
Why?
|
| Depression | 1 | 2019 | 222 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 988 | 0.030 |
Why?
|
| Receptors, Opioid | 1 | 2016 | 26 | 0.030 |
Why?
|
| Receptors, Peptide | 1 | 1996 | 20 | 0.030 |
Why?
|
| Receptors, Bombesin | 1 | 1996 | 6 | 0.030 |
Why?
|
| Oxygen Consumption | 2 | 1995 | 181 | 0.030 |
Why?
|
| Microscopy, Electron | 3 | 2005 | 94 | 0.030 |
Why?
|
| Melanocytes | 1 | 1996 | 13 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1997 | 127 | 0.030 |
Why?
|
| Neuroprotective Agents | 1 | 2016 | 52 | 0.030 |
Why?
|
| Respiratory Burst | 1 | 1996 | 10 | 0.030 |
Why?
|
| Dimerization | 1 | 1996 | 76 | 0.030 |
Why?
|
| Computational Biology | 1 | 2017 | 156 | 0.030 |
Why?
|
| Respiration | 3 | 1994 | 45 | 0.030 |
Why?
|
| Proteome | 1 | 2016 | 78 | 0.030 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 1995 | 4 | 0.030 |
Why?
|
| Opioid-Related Disorders | 1 | 1996 | 42 | 0.030 |
Why?
|
| Stroke Volume | 2 | 1994 | 124 | 0.030 |
Why?
|
| Shock | 1 | 1995 | 17 | 0.030 |
Why?
|
| Malondialdehyde | 1 | 2015 | 7 | 0.030 |
Why?
|
| Histamine | 2 | 1997 | 10 | 0.030 |
Why?
|
| Molecular Structure | 1 | 1996 | 244 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2015 | 28 | 0.030 |
Why?
|
| Vasoconstriction | 3 | 1994 | 45 | 0.030 |
Why?
|
| Intestines | 2 | 1998 | 118 | 0.030 |
Why?
|
| Binding Sites | 1 | 1996 | 354 | 0.030 |
Why?
|
| Biomechanical Phenomena | 2 | 2006 | 182 | 0.030 |
Why?
|
| Parietal Lobe | 1 | 2015 | 27 | 0.030 |
Why?
|
| Temporal Lobe | 1 | 2015 | 32 | 0.030 |
Why?
|
| Hydroxyethyl Starch Derivatives | 1 | 1995 | 1 | 0.030 |
Why?
|
| Amyloid beta-Peptides | 1 | 2015 | 49 | 0.030 |
Why?
|
| Staphylococcus aureus | 2 | 2012 | 121 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 1994 | 12 | 0.030 |
Why?
|
| Tibia | 2 | 2005 | 39 | 0.030 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 1994 | 26 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 1994 | 23 | 0.030 |
Why?
|
| GPI-Linked Proteins | 2 | 2005 | 13 | 0.030 |
Why?
|
| Kidney Cortex | 1 | 1994 | 5 | 0.030 |
Why?
|
| Thrombomodulin | 1 | 1994 | 11 | 0.030 |
Why?
|
| Corneal Injuries | 1 | 2014 | 12 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 1996 | 292 | 0.030 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 1994 | 22 | 0.030 |
Why?
|
| Child | 1 | 2020 | 2271 | 0.030 |
Why?
|
| Religion | 1 | 2014 | 25 | 0.030 |
Why?
|
| Cell Cycle | 2 | 2008 | 162 | 0.030 |
Why?
|
| Hydroxyl Radical | 1 | 1994 | 7 | 0.030 |
Why?
|
| Hybrid Cells | 2 | 1992 | 8 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2015 | 202 | 0.030 |
Why?
|
| Plant Preparations | 1 | 2013 | 5 | 0.030 |
Why?
|
| Intestinal Diseases | 1 | 1994 | 11 | 0.030 |
Why?
|
| Seeds | 1 | 2013 | 14 | 0.030 |
Why?
|
| Blood Pressure | 5 | 1994 | 355 | 0.030 |
Why?
|
| Arginine | 1 | 1994 | 42 | 0.030 |
Why?
|
| Indoles | 1 | 1994 | 110 | 0.030 |
Why?
|
| Dopamine and cAMP-Regulated Phosphoprotein 32 | 1 | 1993 | 3 | 0.030 |
Why?
|
| Chromatography, Affinity | 1 | 1993 | 32 | 0.030 |
Why?
|
| Maze Learning | 1 | 2013 | 78 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 1 | 1993 | 20 | 0.030 |
Why?
|
| Enzyme Inhibitors | 2 | 2008 | 251 | 0.030 |
Why?
|
| Biopsy | 1 | 2014 | 207 | 0.030 |
Why?
|
| Reperfusion Injury | 1 | 1993 | 31 | 0.030 |
Why?
|
| Skin | 1 | 1994 | 151 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2013 | 37 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 233 | 0.020 |
Why?
|
| Adrenalectomy | 2 | 1989 | 13 | 0.020 |
Why?
|
| United States | 1 | 2019 | 2201 | 0.020 |
Why?
|
| Rats, Inbred WF | 2 | 2003 | 11 | 0.020 |
Why?
|
| Glutathione | 1 | 1993 | 76 | 0.020 |
Why?
|
| Surface Properties | 1 | 2013 | 134 | 0.020 |
Why?
|
| Materials Testing | 1 | 2013 | 89 | 0.020 |
Why?
|
| Nephropidae | 1 | 1992 | 1 | 0.020 |
Why?
|
| Sequence Homology | 1 | 1992 | 10 | 0.020 |
Why?
|
| Drosophila | 1 | 1992 | 32 | 0.020 |
Why?
|
| Taurine | 1 | 2012 | 9 | 0.020 |
Why?
|
| Exons | 1 | 1992 | 42 | 0.020 |
Why?
|
| Device Removal | 1 | 2012 | 30 | 0.020 |
Why?
|
| Equipment Design | 1 | 2013 | 218 | 0.020 |
Why?
|
| Choline | 1 | 2012 | 20 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 1997 | 534 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 1992 | 128 | 0.020 |
Why?
|
| Hippocampus | 1 | 2013 | 194 | 0.020 |
Why?
|
| Hemorrhage | 1 | 1994 | 265 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 461 | 0.020 |
Why?
|
| Putamen | 1 | 1991 | 3 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 893 | 0.020 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2012 | 68 | 0.020 |
Why?
|
| Aorta | 1 | 2012 | 124 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2005 | 391 | 0.020 |
Why?
|
| Carcinogens | 2 | 2003 | 39 | 0.020 |
Why?
|
| Pentetic Acid | 1 | 2011 | 4 | 0.020 |
Why?
|
| Precipitin Tests | 1 | 1991 | 47 | 0.020 |
Why?
|
| Adrenal Glands | 1 | 1991 | 21 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 236 | 0.020 |
Why?
|
| Adrenergic beta-2 Receptor Antagonists | 1 | 2011 | 4 | 0.020 |
Why?
|
| Serum Albumin, Bovine | 1 | 2011 | 22 | 0.020 |
Why?
|
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2011 | 4 | 0.020 |
Why?
|
| Biotin | 1 | 2011 | 25 | 0.020 |
Why?
|
| Twist-Related Protein 1 | 1 | 2011 | 5 | 0.020 |
Why?
|
| Exonucleases | 1 | 2011 | 5 | 0.020 |
Why?
|
| 14-3-3 Proteins | 1 | 2011 | 9 | 0.020 |
Why?
|
| Pheromones | 1 | 1991 | 7 | 0.020 |
Why?
|
| Vimentin | 1 | 2011 | 28 | 0.020 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2011 | 23 | 0.020 |
Why?
|
| Receptor, Notch1 | 1 | 2011 | 27 | 0.020 |
Why?
|
| ras Proteins | 1 | 2011 | 43 | 0.020 |
Why?
|
| ROC Curve | 1 | 2011 | 144 | 0.020 |
Why?
|
| Thymus Gland | 1 | 1991 | 54 | 0.020 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2011 | 26 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 1991 | 114 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2011 | 44 | 0.020 |
Why?
|
| Immunoblotting | 1 | 1991 | 124 | 0.020 |
Why?
|
| Templates, Genetic | 1 | 1990 | 10 | 0.020 |
Why?
|
| Species Specificity | 1 | 1991 | 193 | 0.020 |
Why?
|
| Spleen | 2 | 2009 | 113 | 0.020 |
Why?
|
| Hypotension | 1 | 1990 | 19 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 79 | 0.020 |
Why?
|
| Inhalation Exposure | 1 | 2010 | 15 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 209 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 458 | 0.020 |
Why?
|
| Perfusion | 1 | 2010 | 43 | 0.020 |
Why?
|
| Diffusion | 1 | 2010 | 39 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2010 | 103 | 0.020 |
Why?
|
| Cattle | 1 | 1991 | 388 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2000 | 114 | 0.020 |
Why?
|
| Adrenal Insufficiency | 1 | 1989 | 4 | 0.020 |
Why?
|
| Sequence Alignment | 2 | 2002 | 112 | 0.020 |
Why?
|
| Airway Resistance | 1 | 1989 | 4 | 0.020 |
Why?
|
| Pentobarbital | 1 | 1989 | 3 | 0.020 |
Why?
|
| Epitopes | 1 | 1990 | 185 | 0.020 |
Why?
|
| Adenosine Triphosphatases | 1 | 1989 | 50 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 1989 | 115 | 0.020 |
Why?
|
| Lepidoptera | 1 | 1988 | 2 | 0.020 |
Why?
|
| Cerebellum | 1 | 1989 | 41 | 0.020 |
Why?
|
| Netrin-1 | 1 | 2008 | 6 | 0.020 |
Why?
|
| Lens, Crystalline | 1 | 2008 | 6 | 0.020 |
Why?
|
| Vision, Binocular | 1 | 2008 | 8 | 0.020 |
Why?
|
| Electrophoresis | 1 | 2008 | 13 | 0.020 |
Why?
|
| Nerve Growth Factors | 1 | 2008 | 24 | 0.020 |
Why?
|
| Bacteriophage lambda | 1 | 1988 | 3 | 0.020 |
Why?
|
| Immunosorbent Techniques | 1 | 1988 | 12 | 0.020 |
Why?
|
| Sclera | 1 | 2008 | 11 | 0.020 |
Why?
|
| Vitreous Body | 1 | 2008 | 23 | 0.020 |
Why?
|
| Acid Phosphatase | 1 | 2008 | 6 | 0.020 |
Why?
|
| Tartrate-Resistant Acid Phosphatase | 1 | 2008 | 7 | 0.020 |
Why?
|
| Phylogeny | 1 | 1991 | 489 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2008 | 50 | 0.020 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2008 | 24 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2008 | 38 | 0.020 |
Why?
|
| Complement C3c | 1 | 2008 | 3 | 0.020 |
Why?
|
| alpha-Macroglobulins | 1 | 2008 | 4 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 1988 | 137 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 2008 | 20 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2009 | 111 | 0.020 |
Why?
|
| Ceruloplasmin | 1 | 2008 | 10 | 0.020 |
Why?
|
| Trypsin | 1 | 2008 | 24 | 0.020 |
Why?
|
| Plant Extracts | 1 | 2008 | 62 | 0.020 |
Why?
|
| Drug Implants | 1 | 2007 | 14 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2010 | 2402 | 0.020 |
Why?
|
| Listeria monocytogenes | 1 | 2008 | 59 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2007 | 25 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2008 | 107 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2008 | 79 | 0.020 |
Why?
|
| Pulmonary Circulation | 3 | 1997 | 15 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2008 | 191 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2008 | 145 | 0.020 |
Why?
|
| Myocytes, Cardiac | 1 | 2007 | 63 | 0.020 |
Why?
|
| Central Venous Pressure | 3 | 1994 | 4 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2008 | 197 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2007 | 138 | 0.020 |
Why?
|
| Osteoprotegerin | 1 | 2006 | 3 | 0.020 |
Why?
|
| Eye Proteins | 1 | 2008 | 207 | 0.020 |
Why?
|
| RANK Ligand | 1 | 2006 | 19 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2007 | 231 | 0.020 |
Why?
|
| Injections, Intralesional | 1 | 2006 | 6 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2006 | 18 | 0.020 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2006 | 11 | 0.020 |
Why?
|
| Common Bile Duct | 1 | 2005 | 1 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2006 | 132 | 0.020 |
Why?
|
| Carbon Isotopes | 1 | 2005 | 43 | 0.020 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2005 | 7 | 0.010 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2005 | 8 | 0.010 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2005 | 12 | 0.010 |
Why?
|
| Disease Progression | 1 | 2007 | 475 | 0.010 |
Why?
|
| Bone and Bones | 1 | 2006 | 78 | 0.010 |
Why?
|
| I-kappa B Proteins | 1 | 2005 | 11 | 0.010 |
Why?
|
| Administration, Cutaneous | 1 | 2005 | 19 | 0.010 |
Why?
|
| Rats, Long-Evans | 1 | 2005 | 35 | 0.010 |
Why?
|
| Thymidine | 1 | 2005 | 7 | 0.010 |
Why?
|
| Spin Labels | 2 | 1996 | 19 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2008 | 419 | 0.010 |
Why?
|
| Fos-Related Antigen-2 | 1 | 2005 | 1 | 0.010 |
Why?
|
| HCT116 Cells | 1 | 2005 | 53 | 0.010 |
Why?
|
| Absorptiometry, Photon | 1 | 2005 | 100 | 0.010 |
Why?
|
| Transcription Factor AP-1 | 1 | 2005 | 26 | 0.010 |
Why?
|
| Mitochondria | 1 | 2009 | 396 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 224 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2005 | 126 | 0.010 |
Why?
|
| Necrosis | 1 | 2005 | 85 | 0.010 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2005 | 45 | 0.010 |
Why?
|
| Cyclic AMP | 2 | 1996 | 87 | 0.010 |
Why?
|
| Fibrosis | 1 | 2005 | 134 | 0.010 |
Why?
|
| Actins | 1 | 2005 | 99 | 0.010 |
Why?
|
| Piperazines | 1 | 2005 | 50 | 0.010 |
Why?
|
| Microscopy, Video | 1 | 2004 | 18 | 0.010 |
Why?
|
| Cell Shape | 1 | 2004 | 16 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2004 | 60 | 0.010 |
Why?
|
| Prospective Studies | 2 | 1998 | 1272 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2005 | 291 | 0.010 |
Why?
|
| Lipid Peroxidation | 1 | 2004 | 48 | 0.010 |
Why?
|
| Cell Survival | 1 | 2005 | 416 | 0.010 |
Why?
|
| Oncogenes | 1 | 2003 | 34 | 0.010 |
Why?
|
| Transplantation, Isogeneic | 1 | 2003 | 1 | 0.010 |
Why?
|
| Transgenes | 1 | 2003 | 63 | 0.010 |
Why?
|
| Image Cytometry | 1 | 2003 | 2 | 0.010 |
Why?
|
| Ploidies | 1 | 2003 | 6 | 0.010 |
Why?
|
| Nitrosamines | 1 | 2003 | 5 | 0.010 |
Why?
|
| Mesocricetus | 1 | 2003 | 13 | 0.010 |
Why?
|
| Pancreatic Ducts | 1 | 2003 | 10 | 0.010 |
Why?
|
| Markov Chains | 1 | 2003 | 16 | 0.010 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2002 | 1 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 6 | 0.010 |
Why?
|
| Immunoglobulin Fragments | 1 | 2002 | 6 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2002 | 46 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2002 | 43 | 0.010 |
Why?
|
| Enterotoxins | 1 | 2002 | 22 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2002 | 55 | 0.010 |
Why?
|
| Recurrence | 1 | 2003 | 325 | 0.010 |
Why?
|
| Survival Rate | 1 | 2003 | 431 | 0.010 |
Why?
|
| Transcription Factor TFIIIA | 1 | 2002 | 12 | 0.010 |
Why?
|
| Nucleoproteins | 1 | 1981 | 8 | 0.010 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 1995 | 9 | 0.010 |
Why?
|
| Aequorin | 1 | 2001 | 1 | 0.010 |
Why?
|
| Radioligand Assay | 1 | 2001 | 17 | 0.010 |
Why?
|
| Luminescent Measurements | 1 | 2001 | 31 | 0.010 |
Why?
|
| Sequence Analysis, Protein | 1 | 2001 | 15 | 0.010 |
Why?
|
| Electron Spin Resonance Spectroscopy | 2 | 1994 | 35 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2002 | 179 | 0.010 |
Why?
|
| Collagen | 1 | 2002 | 156 | 0.010 |
Why?
|
| Placebos | 1 | 2001 | 48 | 0.010 |
Why?
|
| Litter Size | 1 | 2001 | 12 | 0.010 |
Why?
|
| Organ Size | 1 | 2001 | 88 | 0.010 |
Why?
|
| Carbon Dioxide | 2 | 1994 | 93 | 0.010 |
Why?
|
| Oxidation-Reduction | 2 | 1993 | 366 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 2001 | 67 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2000 | 55 | 0.010 |
Why?
|
| Oxygen | 2 | 1994 | 234 | 0.010 |
Why?
|
| Nitrites | 1 | 2000 | 30 | 0.010 |
Why?
|
| Nitrates | 1 | 2000 | 51 | 0.010 |
Why?
|
| Epinephrine | 2 | 1990 | 37 | 0.010 |
Why?
|
| Body Weight | 1 | 2001 | 250 | 0.010 |
Why?
|
| Protein Binding | 1 | 2002 | 664 | 0.010 |
Why?
|
| Xenopus | 1 | 1999 | 28 | 0.010 |
Why?
|
| Microcirculation | 1 | 2000 | 113 | 0.010 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 1999 | 18 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 1999 | 29 | 0.010 |
Why?
|
| Vagotomy | 1 | 1999 | 21 | 0.010 |
Why?
|
| Parasympatholytics | 1 | 1999 | 13 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 1981 | 166 | 0.010 |
Why?
|
| Corticosterone | 2 | 1989 | 34 | 0.010 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2001 | 126 | 0.010 |
Why?
|
| Atropine | 1 | 1999 | 47 | 0.010 |
Why?
|
| Hemoperitoneum | 1 | 1998 | 1 | 0.010 |
Why?
|
| Embolism, Air | 1 | 1998 | 2 | 0.010 |
Why?
|
| Stromal Cells | 1 | 1998 | 62 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 1998 | 119 | 0.010 |
Why?
|
| Explosions | 1 | 1998 | 17 | 0.010 |
Why?
|
| Adipocytes | 1 | 1998 | 58 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1997 | 43 | 0.010 |
Why?
|
| Leukopenia | 1 | 1997 | 5 | 0.010 |
Why?
|
| Lipid A | 1 | 1997 | 5 | 0.010 |
Why?
|
| Biogenic Monoamines | 1 | 1997 | 3 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 1998 | 256 | 0.010 |
Why?
|
| Ditiocarb | 1 | 1996 | 6 | 0.010 |
Why?
|
| Morphine Dependence | 1 | 1996 | 2 | 0.010 |
Why?
|
| Olfactory Pathways | 1 | 1996 | 9 | 0.010 |
Why?
|
| Autoradiography | 1 | 1996 | 29 | 0.010 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 1996 | 5 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1996 | 37 | 0.010 |
Why?
|
| Pregnancy | 1 | 2001 | 1219 | 0.010 |
Why?
|
| Nucleus Accumbens | 1 | 1996 | 8 | 0.010 |
Why?
|
| Ferric Compounds | 1 | 1996 | 43 | 0.010 |
Why?
|
| Liver Circulation | 1 | 1995 | 1 | 0.010 |
Why?
|
| Reperfusion | 1 | 1995 | 7 | 0.010 |
Why?
|
| Hematocrit | 1 | 1995 | 26 | 0.010 |
Why?
|
| Acidosis, Lactic | 1 | 1995 | 3 | 0.010 |
Why?
|
| Acidosis | 1 | 1995 | 11 | 0.010 |
Why?
|
| Fluid Therapy | 1 | 1995 | 14 | 0.010 |
Why?
|
| Brain Mapping | 1 | 1996 | 207 | 0.010 |
Why?
|
| Cause of Death | 1 | 1995 | 73 | 0.010 |
Why?
|
| Toxemia | 1 | 1994 | 1 | 0.010 |
Why?
|
| Poly A | 1 | 1994 | 5 | 0.010 |
Why?
|
| Colforsin | 1 | 1994 | 12 | 0.010 |
Why?
|
| Receptors, Melatonin | 1 | 1994 | 10 | 0.010 |
Why?
|
| CHO Cells | 1 | 1994 | 96 | 0.010 |
Why?
|
| Protein Structure, Secondary | 1 | 1994 | 130 | 0.010 |
Why?
|
| Vinblastine | 1 | 1994 | 6 | 0.010 |
Why?
|
| omega-N-Methylarginine | 1 | 1994 | 11 | 0.010 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 1994 | 23 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1994 | 102 | 0.010 |
Why?
|
| Acne Vulgaris | 1 | 1953 | 6 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1994 | 257 | 0.010 |
Why?
|
| Glutathione Disulfide | 1 | 1993 | 14 | 0.010 |
Why?
|
| Breast | 1 | 1953 | 52 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1994 | 164 | 0.010 |
Why?
|
| Carcinoma | 1 | 1953 | 74 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1994 | 259 | 0.010 |
Why?
|
| Oxyhemoglobins | 1 | 1991 | 10 | 0.010 |
Why?
|
| Spectrophotometry | 1 | 1991 | 34 | 0.010 |
Why?
|
| Norepinephrine | 1 | 1990 | 32 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 1990 | 27 | 0.010 |
Why?
|
| Hemoglobins | 1 | 1991 | 118 | 0.010 |
Why?
|
| Ca(2+) Mg(2+)-ATPase | 1 | 1989 | 3 | 0.000 |
Why?
|
| Calcium-Transporting ATPases | 1 | 1989 | 9 | 0.000 |
Why?
|
| Myosins | 1 | 1989 | 7 | 0.000 |
Why?
|
| Myofibrils | 1 | 1989 | 5 | 0.000 |
Why?
|
| Dexamethasone | 1 | 1989 | 63 | 0.000 |
Why?
|
| Blood Physiological Phenomena | 1 | 1989 | 2 | 0.000 |
Why?
|
| Isoproterenol | 1 | 1989 | 23 | 0.000 |
Why?
|
| Guinea Pigs | 1 | 1989 | 73 | 0.000 |
Why?
|
| Aerosols | 1 | 1989 | 43 | 0.000 |
Why?
|
| Bronchi | 1 | 1989 | 38 | 0.000 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1989 | 269 | 0.000 |
Why?
|
| Venous Pressure | 1 | 1987 | 2 | 0.000 |
Why?
|
| Portal Vein | 1 | 1987 | 8 | 0.000 |
Why?
|
| Blood Circulation | 1 | 1987 | 13 | 0.000 |
Why?
|
| Blood | 1 | 1987 | 34 | 0.000 |
Why?
|
| Carcinoma, Ehrlich Tumor | 1 | 1981 | 2 | 0.000 |
Why?
|
| RNA Polymerase II | 1 | 1981 | 7 | 0.000 |
Why?
|
| Lupus Vulgaris | 1 | 1981 | 6 | 0.000 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 1981 | 6 | 0.000 |
Why?
|
| Radioimmunoassay | 1 | 1981 | 45 | 0.000 |
Why?
|
| Clone Cells | 1 | 1981 | 22 | 0.000 |
Why?
|
| Mice, Inbred Strains | 1 | 1981 | 61 | 0.000 |
Why?
|